PeriodontitisNCT07695857
Adropin Levels in Periodontal Disease
An observational study of Periodontitis, run by Giresun University at 1 site in Turkey (Türkiye).
Trial summary
This study aimed to evaluate gingival crevicular fluid (GCF) and serum levels of Adropin and tumor necrosis factor (TNF)-alfa in patients with periodontitis before and after non-surgical periodontal therapy. Read more about this study
- Who is it for?
- Ages 27 to 49 yearsHealthy volunteers can take part
- Conditions the study is for
- Periodontitis
- What is being tested?
- Nonsurgical periodontal therapy
- Type of treatment
- Pill or oral medicine, Surgery or procedure
- How many people
- 60 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 2 Apr 2018to 6 Nov 2020
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 27 to 49 years
- All sexes
- Healthy volunteers accepted
- Adult
Study population: Criteria for healthy control group: BOP < 10% and PD ≤ 3 mm without clinical attachment loss or radiographic sign of alveolar bone destruction. Criteria for periodontitis group: interdental CAL ≥ 5 mm at least 2 non-adjacent teeth, PD ≥ 6 mm and radiographic bone loss extending to the mid-third of the root or beyond.
Who may be able to join
- having at least 20 natural teeth, excluding third molars
- having no systemic disease
- non-smokers
- Diagnosed with periodontally health and periodontitis patients
Who cannot join
- having any systemic diseases
- smoking
- current pregnancy or lactation
- a history of periodontal treatment in the past 6 months
- using antibiotic, anti-inflammatory drugs or any other drugs within the past 6 months.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Adropin Levels in GCF and Serum of Periodontitis Patients
This study aimed to evaluate gingival crevicular fluid (GCF) and serum levels of Adropin and tumor necrosis factor (TNF)-alfa in patients with periodontitis before and after non-surgical periodontal therapy.
Read the detailed description
Thirty periodontitis and thirty periodontally healthy individuals were enrolled in the study. Clinical periodontal measurements were recorded; periodontitis patients received non-surgical periodontal treatment, and GCF and serum samples were collected at baseline and at 6 weeks after treatment. Adropin and TNF-alfa were determined by ELISA.
- Conditions
- Periodontitis
- Being tested
- Nonsurgical periodontal therapy
- Keywords
- periodontitis, Adropin, gingival crevicular fluid, serum
- Medical subject headings
- Periodontitis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Nonsurgical periodontal therapyProcedure or surgery
Nonsurgical periodontal therapy includes oral hygiene education and scaling and root planning approaches to eliminate microbial dental biofilm that is the primary etiology of periodontal diseases.
| Study group | Role | What they receive |
|---|---|---|
| Group 1: Periodontally healthy individuals | Not described | |
| Group 2: Periodontitis patients | Not described Receives: Procedure: Nonsurgical periodontal therapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
1. Adropin levels
Changes in Adropin levels before and after periodontal therapy
Measured: Baseline and at 6 weeks after therapy
Secondary outcomes (1)
TNF-alfa levels
Changes in TNF-alfa levels before and after periodontal therapy
Measured: baseline and at 6 weeks after therapy
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Jul 2026
- Study start2 Apr 2018
- Primary completion2 Sep 2020
- Study completion6 Nov 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for PeriodontitisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 60 participants (actual)
Sponsor and investigators
- Lead sponsor
- Giresun University
- Sponsor type
- University, hospital or other
- Collaborators
- Aydin Adnan Menderes University
- Responsible party
- Principal investigator, Zeynep Pınar Yucel, Giresun University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07695857
- Sponsor's protocol ID
- KAEK-37
- Other IDs
- SAĞ-BAP-A-150219-33
- Status last verified
- Jan 2026
- First submitted
- 6 Jul 2026
- Last updated
- 10 Jul 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 10 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Adropin Levels in GCF and Serum of Periodontitis Patients
- ClinicalTrials.gov ID
- NCT07695857
- Acronym / sponsor ID
- KAEK-37
- Conditions
- Periodontitis
- Keywords
- periodontitis, Adropin, gingival crevicular fluid, serum
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 60 participants (actual)
- Lead sponsor
- Giresun UniversityUniversity, hospital or other
- Collaborators
- Aydin Adnan Menderes University
- Study start
- 2 Apr 2018 (actual)
- Primary completion
- 2 Sep 2020 (actual)
- Study completion
- 6 Nov 2020 (actual)
- First posted
- 10 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aimed to evaluate gingival crevicular fluid (GCF) and serum levels of Adropin and tumor necrosis factor (TNF)-alfa in patients with periodontitis before and after non-surgical periodontal therapy.
Detailed description
Thirty periodontitis and thirty periodontally healthy individuals were enrolled in the study. Clinical periodontal measurements were recorded; periodontitis patients received non-surgical periodontal treatment, and GCF and serum samples were collected at baseline and at 6 weeks after treatment. Adropin and TNF-alfa were determined by ELISA.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Group 1: Periodontally healthy individuals | – | – |
| Group 2: Periodontitis patients | – | Procedure: Nonsurgical periodontal therapy |
Who may qualify
- Ages
- 27 to 49 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
- Study population
- Criteria for healthy control group: BOP < 10% and PD ≤ 3 mm without clinical attachment loss or radiographic sign of alveolar bone destruction. Criteria for periodontitis group: interdental CAL ≥ 5 mm at least 2 non-adjacent teeth, PD ≥ 6 mm and radiographic bone loss extending to the mid-third of the root or beyond.
Key inclusion criteria (4 listed)
- having at least 20 natural teeth, excluding third molars
- having no systemic disease
- non-smokers
- Diagnosed with periodontally health and periodontitis patients
Key exclusion criteria (5 listed)
- having any systemic diseases
- smoking
- current pregnancy or lactation
- a history of periodontal treatment in the past 6 months
- using antibiotic, anti-inflammatory drugs or any other drugs within the past 6 months.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Nonsurgical periodontal therapyNonsurgical periodontal therapy includes oral hygiene education and scaling and root planning approaches to eliminate microbial dental biofilm that is the primary etiology of periodontal diseases. | Procedure or surgery | Group 2: Periodontitis patients |
Primary outcome
1. Adropin levels
Time frame: Baseline and at 6 weeks after therapy
Changes in Adropin levels before and after periodontal therapy
1 secondary outcome
TNF-alfa levels
Time frame: baseline and at 6 weeks after therapy
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Jul 2026.
Related trials for Periodontitis
Recruiting
Effect of Cryotherapeutic and Nanotherapeutic Sodium Hypochlorite on Post-Operative Endodontic Pain.
Symptomatic Irreversible Pulpitis, Symptomatic Apical Periodontitis
Active, not recruitingObservational study
A Retrospective Comparative Evaluation of Omega-3 and Resveratrol Supplementation in Patients With Periodontitis
Periodontitis
Recruiting
Probiotics Versus Antibiotics as an Adjuvant to Non-surgical Periodontal Treatment Among Smokers With Stage II, Grade B Periodontitis
Probiotics, Antibiotics
Recruiting
Effects of Different Activation Techniques on Antimicrobial Photodynamic Therapy in Apical Periodontitis
Apical Periodontitis, Endodontic Retreatment
Recruiting
Ozone Gel Versus Chlorohexidine Gel as an Adjunct to Non-Surgical Treatment of Stage II Periodontitis Grade B Among Smokers Patients
Ozone Gel, Chlorohexidine Gel
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Periodontitis, run by Giresun University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 10 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
1. Adropin levels (time frame: Baseline and at 6 weeks after therapy). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Jul 2026.